The Renin-Angiotensin-Aldosterone System and Fibrinolysis in Progressive Renal Disease

2002 ◽  
Vol 22 (5) ◽  
pp. 399-406 ◽  
Author(s):  
Nancy J. Brown ◽  
Douglas E. Vaughan ◽  
Agnes B. Fogo
Keyword(s):  
Renal Disease ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Progressive Renal Disease

Role of the Renin-Angiotensin-Aldosterone System in the Regulation of Plasma Potassium in Chronic Renal Disease

Nephron ◽  
1975 ◽  
Vol 15 (1) ◽  
pp. 35-49 ◽  
Author(s):  
P. Weidmann ◽  
M.H. Maxwell ◽  
P. Rowe ◽  
R. Winer ◽  
S.G. Massry
Keyword(s):  
Renal Disease ◽  
Chronic Renal Disease ◽  
Plasma Potassium ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin

scholarly journals Advances in the Renin-Angiotensin-Aldosterone System: Relevance to Diabetic Nephropathy

2008 ◽  
Vol 8 ◽  
pp. 434-445 ◽  
Author(s):  
Audrey Koitka ◽  
Christos Tikellis
Keyword(s):  
Diabetic Nephropathy ◽  
Angiotensin Ii ◽  
Angiotensin Converting Enzyme ◽  
Renal Disease ◽  
Converting Enzyme ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Angiotensin Type 2 Receptor

Hypertension is now recognized as a key contributory factor to the development and progression of kidney disease in both type 1 and type 2 diabetes. The renin angiotensin system (RAS) and its effector molecule angiotensin II, in particular, have a range of hemodynamic and nonhemodynamic effects that contribute not only to the development of hypertension, but also to renal disease. As a result, therapeutic inhibition of the RAS with angiotensin-converting enzyme inhibitors and/or selective angiotensin II type 1 receptor blockers has been proposed as a key strategy for reducing kidney damage beyond the expected effects one would observe with blood pressure reduction per se. Although the relationship between the RAS and the progression of diabetic renal disease has been known for many decades, recent advances have revealed a more complex paradigm with the discovery of a number of new components. Thus, further understanding of these new components of the renin angiotensin aldosterone system (RAAS), such as the angiotensin type 2 receptor subtype, angiotensin converting enzyme 2, and the recently cloned renin receptor, is likely to have therapeutic implications for disorders such as diabetic nephropathy, where interruption of the RAAS is widely used.

scholarly journals Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients With Type 2 Diabetes: An Asian perspective from the RENAAL study

Diabetes Care ◽  
2004 ◽  
Vol 27 (4) ◽  
pp. 874-879 ◽  
Author(s):  
J. C.N. Chan ◽  
N. M.S. Wat ◽  
W.-Y. So ◽  
K. S.L. Lam ◽  
C.-T. Chua ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin

Dual blockade of the renin–angiotensin–aldosterone system in renal disease: what is the future? Authors' reply

2014 ◽  
Vol 124 (1-2) ◽  
pp. 73-74
Author(s):  
Sławomir Lizakowski ◽  
Leszek Tylicki ◽  
Przemysław Rutkowski ◽  
Bolesław Rutkowski
Keyword(s):  
Renal Disease ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
The Future ◽  
Dual Blockade

Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease

2016 ◽  
Vol 351 (3) ◽  
pp. 309-316 ◽  
Author(s):  
Teresa Slomka ◽  
Emily S. Lennon ◽  
Hina Akbar ◽  
Elvira O. Gosmanova ◽  
Syamal K. Bhattacharya ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document